Find out more about Mariana's work in the following media outlets:
Television
Academic expert in 'Inside Story', 22 minute TV programme on Toyota Recall and its impact. Presented by Mike Hanna. Produced by Al Jazeera English, first aired prime time on Al Jazeera English TV, 7 February 2010
Key role in the design and development of the film 'Rules of the Game', 30 minute TV film on innovation and the industry life-cycle, Featuring work and interviews by academic experts: Mariana Mazzucato, Paul David, and Clive Sinclair. Presented by PY Gerbeau. Produced by BBC, first aired prime time on BBC2, June 2002.
News
'Is R&D spending worth it?' (forthcoming Spring 2010) - contribution to the 'Excellence in Leadership', the Chartered Institute of Management Accountants business publication
'Economic Insight' column (Jan 2010) - opinion piece on 'to what extent throwing money at funding innovation helps keep a country ahead in the knowledge economy' in the Business XL publication
'Fixing the Broken Innovation Model' (Dec 2009) - opinion piece for Pharmaceutical Executive Europe
'Innovate to Stimulate' (Jan 2010) - article on Prof Mazzucato's inaugural address (25 March 2009): 'Do the best firms always win?' featured in Sesame magazine.
'Economic Recovery is a Slow and Painful Process' (Nov 2009) - Peter Bartram from the Financial Director quoting Professor Mazzucato on the economic growth rate in 2010.
'Winning Advantage Through Innovation' (Nov 2009) - Brett Matthews from the Business Today quoting Professor Mazzucato on why people are not investing and a discussion piece on the relationship between innovation and company growth.
'Study Probes Role of Finance in the Economy' (July 2009) - Market Research Industry Online highlights FINNOV, the OU grant awarded by the European Commission (http://www.finnov-fp7.eu/), led by Mariana Mazzucato
Showing posts with label pharmaceutical companies. Show all posts
Showing posts with label pharmaceutical companies. Show all posts
Friday, 26 February 2010
Tuesday, 28 April 2009
Something to feel good about
By Joanna Chataway, Innogen Co-Director
I don’t know how significant this is but on the face of it the University of Edinburgh should feel proud of itself this week. The University, under pressure from students, has said it will not license its science and technology to pharmaceutical companies that won’t sell their drugs at cost price to developing countries. Edinburgh is the first university to implement such a scheme. A longer article appears in the Observer (26 April 09).
The potential significance of this scheme is that other universities and public sector bodies might follow. With more and more patents owned by the public sector this might have quite an impact on availability of drugs in poor countries. I guess one could argue that this might be gesture politics but it will amount to more than that and anyway that in itself does not make this unimportant. Real change in making affordable drugs available to poor people in developing countries may depend on multiple factors (see Innogen’s OECD report on Health Biotechnology to 2030 for an idea of some the issues) but schemes like the one just announced by the University of Edinburgh are vital in signalling that the current situation whereby people die in their millions of totally preventable diseases must end.
I don’t know how significant this is but on the face of it the University of Edinburgh should feel proud of itself this week. The University, under pressure from students, has said it will not license its science and technology to pharmaceutical companies that won’t sell their drugs at cost price to developing countries. Edinburgh is the first university to implement such a scheme. A longer article appears in the Observer (26 April 09).
The potential significance of this scheme is that other universities and public sector bodies might follow. With more and more patents owned by the public sector this might have quite an impact on availability of drugs in poor countries. I guess one could argue that this might be gesture politics but it will amount to more than that and anyway that in itself does not make this unimportant. Real change in making affordable drugs available to poor people in developing countries may depend on multiple factors (see Innogen’s OECD report on Health Biotechnology to 2030 for an idea of some the issues) but schemes like the one just announced by the University of Edinburgh are vital in signalling that the current situation whereby people die in their millions of totally preventable diseases must end.
Subscribe to:
Posts (Atom)